Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPG 10101 Combination Therapy for Hepatitis C
NCT00277238Phase 2Completed
- Sponsor
- Pfizer
- Start
- Feb 2006
- Primary completion
- Jul 2007
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
A Phase 2 trial of CPG 10101 in hepatitis C (HCV), sponsored by Pfizer. Started Feb 2006; status: completed.
02
Drugs
CPG 10101
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00277238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00277238.